| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Olaparib (JAN/USAN/INN); Lynparza (TN) | ||||||||||
| Product | LYNPARZA (AstraZeneca Pharmaceuticals LP) | ||||||||||
| Formula | C24H23FN4O3 | ||||||||||
| Exact mass | 434.1754 | ||||||||||
| Mol weight | 434.4628 | ||||||||||
| Structure |  | ||||||||||
| Class | Antineoplastic DG02942 PARP inhibitor Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antineoplastic, PARP inhibitor | ||||||||||
| Disease | Ovarian cancer [DS:H00027] Ovarian cancer (BRCA-mutated) [DS:H00027] Ovarian cancer (HRD-positive) [DS:H00027] Breast cancer (BRCA-mutated, HER2-negative) [DS:H00031] Pancreatic adenocarcinoma (BRCA-mutated) [DS:H00019] Prostate cancer (HRR gene-mutataed) [DS:H00024] | ||||||||||
| Comment | PARP inhibition in BRCA1 [HSA:672] [KO:K10605] and BRCA2 [HSA:675] [KO:K08775] -mutation | ||||||||||
| Target | PARP1 [HSA:142] [KO:K24070] PARP2 [HSA:10038] [KO:K10798] | ||||||||||
| Pathway |
| ||||||||||
| Metabolism | Enzyme: CYP3A [HSA:1576 1577 1551] | ||||||||||
| Interaction | |||||||||||
| Other map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01X OTHER ANTINEOPLASTIC AGENTS L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors L01XK01 Olaparib D09730 Olaparib (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Olaparib D09730 Olaparib (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D09730 Olaparib (JAN/USAN/INN) Drug groups [BR:br08330] Antineoplastic DG02942 PARP inhibitor D09730 Olaparib Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate D09730 Olaparib Drug classes [BR:br08332] Antineoplastic DG02942 PARP inhibitor D09730 Olaparib Target-based classification of drugs [BR:br08310] Enzymes Transferases (EC2) Pentosyltransferases PARP1 D09730 Olaparib (JAN/USAN/INN) <JP/US> PARP2 D09730 Olaparib (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D09730 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D09730 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D09730 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D09730 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D09730 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D09730 | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 32 1 C8x C 14.9800 -23.2400 2 C8x C 14.9800 -21.8400 3 C8x C 16.1700 -21.1400 4 C8y C 17.4300 -21.8400 5 C8y C 17.4300 -23.2400 6 C8x C 16.1700 -23.9400 7 C8y C 18.6200 -21.1400 8 N5x N 19.8100 -21.8400 9 N4x N 19.8100 -23.2400 10 C8y C 18.6200 -23.9400 11 O5x O 18.6200 -25.3400 12 C1b C 18.6200 -19.7400 13 C8y C 19.8100 -19.0400 14 C8x C 19.8100 -17.6400 15 C8x C 21.0700 -16.9400 16 C8y C 22.2600 -17.6400 17 C8y C 22.2600 -19.0400 18 C8x C 21.0700 -19.7400 19 X F 23.4500 -16.9400 20 C5a C 23.4500 -19.7400 21 N1y N 24.6400 -19.0400 22 O5a O 23.4500 -21.1400 23 C1x C 24.6400 -17.6400 24 C1x C 25.9000 -16.9400 25 N1y N 27.0900 -17.6400 26 C1x C 27.0900 -19.0400 27 C1x C 25.9000 -19.7400 28 C5a C 28.2800 -16.9400 29 C1y C 29.4700 -17.6400 30 O5a O 28.2800 -15.5400 31 C1x C 30.8700 -17.6400 32 C1x C 30.1700 -18.8300 BOND 36 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 4 7 1 8 7 8 2 9 8 9 1 10 9 10 1 11 5 10 1 12 10 11 2 13 7 12 1 14 12 13 1 15 13 14 2 16 14 15 1 17 15 16 2 18 16 17 1 19 17 18 2 20 13 18 1 21 16 19 1 22 17 20 1 23 20 21 1 24 20 22 2 25 21 23 1 26 23 24 1 27 24 25 1 28 25 26 1 29 26 27 1 30 21 27 1 31 25 28 1 32 28 29 1 33 28 30 2 34 29 31 1 35 31 32 1 36 32 29 1 |